PFE - Pfizer Inc.
| Previous close | 33.46 |
| Open | 33.66 |
| Bid | 33.81 x 3000 |
| Ask | 33.83 x 2200 |
| Day's range | 33.49 - 34.04 |
| 52-week range | 27.88 - 43.23 |
| Volume | 23,205,943 |
| Avg. volume | 27,887,676 |
| Market cap | 187.92B |
| Beta (5Y monthly) | 0.68 |
| PE ratio (TTM) | 12.09 |
| EPS (TTM) | 2.80 |
| Earnings date | 28 Jul 2020 |
| Forward dividend & yield | 1.52 (4.54%) |
| Ex-dividend date | 30 Jul 2020 |
| 1y target est | 40.04 |
- Motley Fool
3 Top Healthcare Stocks to Buy Right Now
Investors often consider the healthcare sector a "defensive" one because people get sick in good economic times and bad. The healthcare sector has been thrown into turmoil with stay-at-home orders and clinic closures. BioNTech (NASDAQ: BNTX), NeoGenomics (NASDAQ: NEO), and Illumina (NASDAQ: ILMN) are three companies that should come through the pandemic era stronger than ever.
- Motley Fool
Moderna and Other Coronavirus Vaccine Developers to Testify in Congress July 21
Moderna (NASDAQ: MRNA) has a date with Congress. Officials from those companies will field questions from the committee's oversight and investigations subcommittee on the current state of their vaccine development processes.
- Motley Fool
Pfizer and BioNTech's Coronavirus Vaccine Ready for Regulatory Submission in December, Maybe Earlier
BioNTech (NASDAQ: BNTX) and Pfizer (NYSE: PFE) are right on the heels of Moderna (NASDAQ: MRNA) in the race to potentially develop a messenger RNA (mRNA) vaccine against SARS-CoV-2, the novel coronavirus that causes COVID-19. In an interview with The Wall Street Journal, BioNTech CEO Ugur Sahin predicted the companies will have enough data for a vaccine to be ready for approval by December. The companies are still trying to figure out which of multiple vaccine candidates should be taken into a 30,000-patient phase 2/3 clinical trial that is scheduled to start this month.
- Yahoo Finance
Coronavirus update: Florida sees deadliest day yet as US cases spike, economy jitters grow
The U.S. saw yet another day of record coronavirus casualties on Thursday, led mostly by a relentless surge in the stricken Sun Belt region.
- Business Wire
Pfizer Pledges $100 Million to New Industry Fund to Help Fight Growing Threat of Antimicrobial Resistance
Pfizer Inc. (NYSE: PFE) announced today it has pledged $100 million to the new Antimicrobial Resistance (AMR) Action Fund, which launched today, to help address the significant global public health need for new antibiotics due to the rapid rise of antibiotic-resistant infections.
- Motley Fool
Here's Why Pfizer Fell 14% in June
The pharma giant missed an opportunity for growth as breast cancer treatment Ibrance failed a key clinical trial.
- Yahoo Finance
Coronavirus update: US cases spike above 3M as WHO withdrawal draws more critics
The U.S. topped 3 million coronavirus cases Wednesday after setting a new record of 60,000 daily cases in the previous day.
- Yahoo Finance
We met with Facebook CEO Mark Zuckerberg and COO Sheryl Sandberg and we got nothing: NAACP CEO
Yahoo Finance speaks with NAACP CEO Derrick Johnson about Facebook's misinformation problems.
- Motley Fool
Here's Why BioNTech Gained 34.8% in June
Shares of BioNTech (NASDAQ: BNTX) rose 34.8% last month, according to data provided by S&P Global Market Intelligence. The German biopharma announced progress in efforts to develop a safe and effective vaccine against SARS-CoV-2, the coronavirus that causes COVID-19, with partner Pfizer. In mid-June, BioNTech announced it had received access to roughly $112 million in debt financing from the European Investment Bank.
- Zacks
Pfizer (PFE) Dips More Than Broader Markets: What You Should Know
Pfizer (PFE) closed the most recent trading day at $34.03, moving -1.39% from the previous trading session.
- Motley Fool
Does Pfizer's COVID-19 Vaccine Make the Big Pharma Stock a Buy?
Investors have reason to be excited after the update from Pfizer and BioNTech. Researchers evaluating the efficacy of COVID-19 vaccine candidates especially look for the production of antibodies that bind to the novel coronavirus and antibodies that neutralize the virus. Seven days after the second dosing of the vaccine, all participants who took the 10-microgram or 30-microgram dose had significantly elevated binding antibodies and neutralizing antibodies.
- Zacks
Is it the Right Time to Invest in Momentum ETFs? Let's Explore
Here we discuss whether it will be wise to invest in momentum ETFs now as the U.S. manufacturing is showing signs of recovery along with improvements in the jobs market.
- Yahoo Finance
Facebook has an incredible challenge in front of it: Goldman Sachs strategist
Facebook won't overcome the yawning advertiser revolt in response to hate content overnight, suggests a Goldman Sachs strategist that specializes in tech investing.
- Zacks
Moderna Shares Lose Momentum After Meteoric Rise: Here's Why
The encouraging progress with mRNA-based coronavirus vaccine drives meteoric rise in Moderna's (MRNA) shares. However, a rumored concern leads to correction.
- Zacks
Biotech ETFs to Gain as Coronavirus Vaccine Hopes Strengthen
As the coronavirus outbreak continues to aggravate, investors are eyeing developments in vaccine or treatments to combat the pandemic.
- Zacks
Pharma Stock Roundup: PFE's Coronavirus Vaccine Study, Approvals in Focus
Pfizer (PFE) releases promising early results from its COVID-19 vaccine study. Several new drug/line extensions get approval in the United States, EU and Japan.
- Zacks
Pfizer Reports Encouarging Data From Coronavirus Program
Pfizer (PFE) announces promising preliminary data on a vaccine candidate from its early-stage coronavirus program under which it is developing four mRNA-based vaccine candidates.
- Zacks
Amgen Gets Favorable Appeals Court Ruling for Enbrel Patent
An appeals court ruled in Amgen's (AMGN) favor in a case challenging the validity of two patents on its top-selling medicine, Enbrel.
- Zacks
Stock Market News for Jul 2, 2020
The Nasdaq and the S&P 500 closed higher on Wednesday as investors focused on signs of economic recovery and better than expected economic data.
- Motley Fool
2 Healthcare Stocks That Could Soar in 2020
As a result, America is the only developed country in the world where cases of the deadly respiratory illness are marking new all-time highs. Since the beginning of the year, shares of telemedicine giant Teladoc Health (NYSE: TDOC) have rallied by 128%. In the first quarter of 2020, new registrations on Teladoc's platform surged by more than 125% over the prior year.
- Bloomberg
Markets May Have a Reason to Rise Along With Covid-19 Cases
(Bloomberg Opinion) -- The Nasdaq Composite hit a record Wednesday, as the S&P 500 rose for the third straight day. This happened even with the Covid-19 pandemic growing in multiple states, and on the same day California and New York rolled back plans to allow restaurants to serve customers indoors.Anyone looking for a convergence between markets and the state of the economy can point to the pullback in travel-related stocks since the growth in the number of coronavirus cases in Arizona, Florida and Texas began in early June. But with Wednesday bringing good news about a vaccine candidate from Pfizer Inc. and BioNtech SE, and with Phase 3 trials for other vaccines set to begin this month, we could begin seeing an even bigger divergence between the real-time economic data and a rosier future priced in by markets.Up until now, there’s an argument that markets have largely followed the progression of the virus and economic momentum, even if markets are priced for a much stronger economic environment than the U.S. was experiencing at July’s onset. Stocks crashed between the latter part of February and the latter part of March as awareness grew about the spread of the virus and the U.S. saw a rolling wave of shutdowns of various forms of economic activity. Stocks bottomed on March 23, the same week that initial jobless claims peaked at 6.8 million.The early part of April through the early part of June was the sweet spot for the progression of the virus, the economic recovery and the stock market. The 7-day moving average of new virus cases in the U.S. initially peaked on April 10, which happened to be the low point for hotel occupancy and passenger air traffic. Stocks rallied as the economy was reopening, jobless claims were falling and virus case counts were declining even as the amount of testing was increasing.But since the early part of June there’s been a setback. Virus case counts reached new highs in some Southern states that reopened their economies after they weren’t hit as hard by Covid-19 in March and April. The Airline Index has fallen over 25% from its June 8 peak, some governors have ordered bars and dine-in restaurants closed again, states in the Northeast are imposing quarantines on visitors from hot spots, and there are signs that credit card spending may be slowing. For the first month since March, we could see both a worsening public health crisis and a deterioration in the economic data in July.At the same time, the timeline for a vaccine and intermediate medical treatments may be getting closer. Moderna Inc. is expected to begin Phase 3 trials for its vaccine candidate in July, with up to 30,000 people getting a small dose. Other vaccine candidates are close behind, with Pfizer and BioNtech’s entry proving safe and to have prompted patients to produce antibodies in a small early trial. On Tuesday, infectious-disease expert Anthony Fauci repeated before Congress that a vaccine could be widely available by early 2021, and the Food and Drug Administration re leased its guidelines for approving inoculations. Although there’s no guarantee that we’ll ever have a vaccine, it may not be long before the conventional wisdom on vaccine availability shifts from 12 to 18 months to more like within 6 months.Over the next month or two then, we could be grappling with the conflicting narratives of a worsening pandemic but more clarity around the timeline and effectiveness of an eventual vaccine. It’s possible that markets, like they were in March, will be gripped by the fear and uncertainty about knock-on effects from the pandemic hurting economic activity, employment and corporate profits. But it’s just as possible that if investors have more confidence that there’s light at the end of the tunnel, markets will look past whatever deterioration we get in the short-term with their focus turning to an end to the public health crisis and a stronger economic recovery in 2021.This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Conor Sen is a Bloomberg Opinion columnist. He has been a contributor to the Atlantic and Business Insider.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
- Investing.com
Stocks - U.S. Futures Higher; Jobs Data Ahead
U.S. stocks are set to open higher Thursday, rallying ahead of the three-day weekend amid growing confidence of an economic recovery despite the resurgence of Covid-19 cases in many states. At 7:05 AM ET (1105 GMT), S&P 500 Futures traded 21 points, or 0.7%, higher, Nasdaq Futures up 45 points, or 0.4%. The Dow Futures contract rose 259 points, or 1%.
- Investing.com
Dollar Weakens; Potential Vaccine Boosts Risk Sentiment
The dollar was on the defensive in early European trade Thursday, with traders turning to perceived riskier currencies amid optimism surrounding a potential Covid-19 vaccine as well as solid economic data. News emerged late Wednesday that a potential Covid-19 vaccine developed by Pfizer (NYSE:PFE) and Biontech (NASDAQ:BNTX) produced positive results in early-stage human trials, raising optimism that an antidote to the virus which has infected over 10 million and killed over 500,000 people can be found. This followed economic data which had suggested that a global recovery is starting to gain momentum: U.S. manufacturing activity rebounded more than expected in June, with the manufacturing activity index by the Institute for Supply Management, released Wednesday, hitting its highest in 14 months.
- Investing.com
Stocks - Europe Seen Higher on Virus Vaccine Optimism
Elsewhere, gold futures fell 0.2% to $1,776.35/oz, while EUR/USD traded at 1.1270, up 0.2% on the day.
